AQR Capital Management
AVTX icon

AQR Capital Management’s Avalo Therapeutics AVTX Stock Holding History

AQR Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-32
Closed -$156K – 2216
2021
Q4 		$156K Buy
32
+23
+256% +$138K ﹤0.01% 2117
2021
Q3 		$56K Buy
+9
New +$73K ﹤0.01% 2223

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AQR Capital Management's AVTX Position: Q1 2022 in Review

AQR Capital Management sold out of Avalo Therapeutics (AVTX) in Q1 2022, closing a stake of 32 shares — an estimated $156K sold.

AQR Capital Management first reported a position in AVTX in Q3 2021 and held it in 2 quarters. The position peaked at $156K in Q4 2021. 65 funds tracked by Wall St. Rank hold AVTX as of Q1 2022.

  • AQR Capital Management reported no remaining Avalo Therapeutics position as of Q1 2022 after selling out during the quarter.
  • AQR Capital Management sold 32 Avalo Therapeutics shares in Q1 2022, an estimated $156K.
  • AQR Capital Management first reported a position in Avalo Therapeutics in Q3 2021 and held it in 2 quarters.
  • AQR Capital Management's Avalo Therapeutics position peaked at $156K in Q4 2021.
  • 65 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2022.

Based on AQR Capital Management's 13F filing for Q1 2022, filed 16 May 2022.